Ketamine therapy has become known for its effects at combating depression and other mood disorders. There’s a growing body of ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

Respondents who said they used other drugs recreationally were also likelier to say they used ketamine during the past year ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Ketamine, the controlled drug best known as a horse tranquilizer or party supplement, has in the last four years become a ...

The FDA approved Johnson & Johnson's Spravato, a ketamine-based nasal spray, to treat adults with major depressive disorder ...